Manchin to review Mylan response to criticism over EpiPens

Manchin to review Mylan response to criticism over EpiPens


1 photo
Save Story
Leer en español

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

CHARLESTON, W.Va. (AP) — U.S. Sen. Joe Manchin says he's concerned about skyrocketing prices for life-saving allergy injection pens made by a company headed by his daughter.

In a news release Thursday, the West Virginia Democrat says he plans a detailed review of drugmaker Mylan's response to criticism about the cost of EpiPens.

Manchin's daughter, Heather Bresch, is CEO of Mylan. She told CNBC Thursday that lowering the price wasn't an option.

Manchin says he plans to work with others to reduce prescription drug prices.

According to the Elsevier Clinical Solutions' Gold Standard Drug Database, a two-dose package that cost around $94 nine years ago has risen more than 500 percent to an average cost of $608 in May. The hike has been criticized by Democratic presidential candidate Hillary Clinton and members of Congress.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Photos

Most recent Business stories

Related topics

Business
The Associated Press

    STAY IN THE KNOW

    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast